Flow Neuroscience has reached a major milestone with the approval of its transcranial direct current stimulation (tDCS) headset by the Australian Therapeutics Goods Administration (TGA). The device is now officially listed on the Australian Register for Therapeutic Goods (ARTG), making it available to people living with depression across the country.

The Flow tDCS Headset offers a safe, non-pharmacological option for managing depression, providing an at-home, evidence-based intervention. This development comes at a critical time: nearly one in five Australians experience depressive episodes, while mental health service wait times have tripled over the past decade.

According to Flow Neuroscience CEO Erin Sivyer Lee, at-home treatments like Flow can help reduce strain on healthcare systems, provide timely relief, and potentially prevent escalation to emergency care. By bringing clinically validated, user-friendly options directly to patients, Flow aims to expand access to mental health support and empower individuals to manage their wellbeing in a flexible, accessible way.

With this TGA approval, Flow Neuroscience continues its mission to make effective, evidence-based mental health care more widely available, supporting people to live fuller, healthier lives.

Learn more about Flow Neuroscience and their TGA-approved tDCS headset.